MarketVIEW Forecast  ·  May 2026 Edition  ·  Live-tracked to 27 Jul 2026

Seasonal Influenza Vaccines
Global Forecast

The independent global influenza vaccine demand model -48 countries, all major manufacturers, mRNA landscape and a new decade outlook to 2040. Now tracking CSL Seqirus' Aujemflu through EU CHMP opinion, UK MHRA approval and JCVI's 2027/28 advice as it lands. The market is larger and more contested than the headlines suggest.

Aujemflu: EU & UK Tracked 48 Countries New 2031-2040 Decade mRNA Outlook Revised May 2026 Update Disruptor Analysis
Product catalogue
VAMV036
Published May 2026

Previous edition
July 2024
Format
MS Excel + presentation
Countries modelled
48
Forecast horizon
To 2040
Manufacturers covered
All major players
mRNA section
Yes - revised
Aujemflu milestones
Tracked to Jul 2026
644m
Doses consumed
globally, 2025
$7.3bn
Global market
value, 2025
48
Countries
modelled
2040
New decade
outlook added
Scope of analysis

Six dimensions - one model

The May 2026 edition is a major refresh of the VacZine Analytics influenza model, covering current market dynamics, manufacturer strategies, mRNA pipeline and - for the first time - a complete decade outlook to 2040.

🌍
Global demand model

48-country volume and value model spanning USA, Canada, EU, and 37 emerging/ROW markets including PAHO nations. Dose and revenue outputs by region, fully validated against manufacturer-reported revenues.

📈
Manufacturer competitive analysis

Sanofi, CSL Seqirus, GSK and ModernaTX analysed in depth - revenue trends, pricing strategy, pipeline progression and positioning, including CSL's newly-approved Aujemflu (adjuvanted, cell-based, 50+) and its EU/UK regulatory path. Who is gaining share and who is under pressure.

🧬
mRNA landscape - radically revised

The mRNA opportunity has been substantially re-scoped since 2024. The model details why, what it means for total market value to 2030 and which programmes still hold commercial promise.

⚡
Disruptor product analysis

CD388/MK-1406 (Merck & Cidara) and universal vaccine approaches assessed for their capacity to reshape the prevention market - not just redistribute it. A key upside scenario not yet in the base case.

🔭
New: 2031-2040 decade outlook

First edition to model the full 2031-2040 window. Where combination and mRNA vaccines are assumed to finally gain traction. Global CAGR and USA value trajectory fully modelled.

⚖️
Forecast risks - explicitly quantified

Four key risks assessed: US coverage suppression under RFK Jr. environment, mRNA pricing resistance ex-US, payor burden from concurrent innovation and the CD388 Phase 3 upside. Transparent methodology.

Why this edition matters

The biggest forecast revision in the model's history

Between July 2024 and May 2026, the global market outlook shifted materially. The 2030 global market value has been cut by over $3bn - and the model explains exactly why, and what the implications are for commercial strategy.

2030 global market - revised
$8.7bn $12.0bn
Global value CAGR 2021-2030 cut from +5.27% to +1.54%.
The mRNA hypothesis that drove the prior estimate has not materialised on schedule.
mRNA revenues 2030 - global
~$1.44bn
Down from $3.4bn in the July 2024 model -16% of market vs 29%
Moderna mRNA-1010 (mFLUSIVA) - FDA decision
Approved 5 Aug 2026
FDA approved mFLUSIVA - full approval for adults 50-64, accelerated approval for 65+ pending confirmatory data. First mRNA flu vaccine to reach market - model captures commercial launch scenarios. Commercial launch is complicated by a stalled US recommendation process: in Sep 2026 CDC quietly kept its prior-season flu guidance in place, citing "legal uncertainties," leaving mFLUSIVA off the recommended list after ACIP was sidelined by litigation over its RFK Jr.-era reconstitution - access for now rests on medical-society guidance and insurer follow-through rather than a formal ACIP vote. On 5 Nov 2026, Health Canada authorised both mFLUSIVA and Moderna's combination flu/COVID-19 mRNA vaccine mCOFLU (mRNA-1083) for adults 50+ - the first market to clear both products together, extending mRNA flu's regulatory footprint beyond the US even as the domestic launch stalls. mCOFLU had separately secured EU authorisation (as mCOMBRIAX) in April 2026.

USA market - estimated 2025 revenue share

Sanofi Pasteur
$1,540m
CSL Seqirus
>$1bn
GSK
$277m

USA FY2025/26 season estimates. Full country-level value and volume outputs in the licensed model.

Live regulatory tracker · updated 22 September 2026

Aujemflu clears the EU and UK gauntlet - JCVI advice locks in a 2027/28 launch

CSL Seqirus' Aujemflu - a trivalent, adjuvanted, cell-culture influenza vaccine (aIIVc) for adults 50 and over - has moved through four regulatory, advisory and commercial milestones since June 2026. The model captures each one and what it means for CSL's positioning against Fluad and Sanofi's HD franchise.

🇬🇧
4 Jun 2026 - MHRA marketing authorisation

Seqirus UK Limited granted UK approval for adults aged 50 and over - CSL's first adjuvanted, cell-based authorisation for a seasonal (non-pandemic) indication in a major regulated market.

🤝
22 Sep 2026 - UK confirms world-first launch, extends pandemic deal

CSL Seqirus and UKHSA extended their pandemic-preparedness Advance Purchase Agreement through 2031, covering 100m+ pandemic influenza doses from the Liverpool site, and confirmed the UK will be the first country worldwide to roll out Aujemflu - from the 2027/28 season, for adults 65+ and at-risk 50-64s.

🇪🇺
25 Jun 2026 - CHMP positive opinion

EMA's CHMP recommended EU-wide marketing authorisation for adults 50+, based on a 7,699-subject trial showing a stronger immune response than a quadrivalent adjuvanted egg-based comparator. Formal EC decision typically follows within ~2 months of CHMP opinion - due imminently.

📋
16 Jul 2026 - JCVI 2027/28 advice

JCVI named Aujemflu (aIIVc) a preferred option for adults 65+ and for 50-64s in a clinical risk group, alongside aIIV, IIVc, IIV-HD and IIVr. First eligible UK procurement season is 2027/28, not 2026/27.

⏳
Moderna mRNA-1010 - deferred, not derailed

JCVI reviewed Moderna's quadrivalent mRNA candidate alongside Aujemflu but judged it unlikely to be procurement-ready for 2027/28 - pushing the UK's first mRNA-flu decision point further out and handing CSL a clearer near-term runway.

Seven storylines in the 2026 edition

The market is moving - in more than one direction

The May 2026 model covers a market under simultaneous pressure from volume contraction, policy headwinds, mRNA delay and the first credible disruptor technologies in decades.

Volume & value

US volume contracted 23% since 2021/22 - but value held

Distributed doses fell to ~132m in early 2025 from 145m a year earlier. Yet pricing strategy by Sanofi and CSL Seqirus protected aggregate value. The model breaks this apart market by market.

mRNA pipeline

Sanofi exited. CSL quietly shelved. Moderna persisted. GSK now enters Phase 3.

The mRNA landscape is no longer a three-way split. On 1 Sep 2026 GSK announced it will advance its mRNA candidate FLUm3HA.b-3NA - targeting both haemagglutinin and neuraminidase - into Phase 3 after Phase II data showed higher immune responses than licensed standard- and high-dose inactivated comparators in adults 18+. It is the first Phase 3 trial of a dual-antigen (HA+NA) mRNA flu vaccine, adding a fourth mRNA contender alongside Moderna's marketed mFLUSIVA, Sanofi/Novavax's protein-combo pivot and CSL's continued silence. The full commercial implications are modelled.

Competitive dynamics

The cell-based vs egg-based battle is accelerating

CSL Seqirus is sunsetting its egg-based Afluria-TIV while expanding Flucelvax globally. Flucelvax private list price: $43.54/dose for 2026/27 - a widening premium over egg-based standard TIVs at ~$20-21. Aujemflu, CSL's new adjuvanted cell-based vaccine for 50+, adds a second cell-based flank - MHRA and CHMP sign-off secured mid-2026, JCVI advising its use from 2027/28.

Policy risk

RFK Jr. & BARDA cuts - a structural headwind not yet in most models

HHS anti-vaccine environment and BARDA mRNA funding cancellations represent a structural risk to US coverage rates in 2026/27 and beyond. This edition explicitly assesses the scenario - and its limits.

Differentiation

FLUNITY-HD: first vaccine to show superior hospitalisation protection in 65+

Sanofi's Fluzone-HD/Efluelda® Lancet data (October 2025) is a landmark result. The model assesses whether this data is enough to unlock JCVI preference in the UK and reinforce premium pricing in Germany. That German/French marketing push triggered formal EU antitrust scrutiny - the European Commission opened proceedings on 26 June 2026 over claims Sanofi's campaign disparaged CSL's Fluad, and on 14 Oct 2026 accepted Sanofi's commitments and made them legally binding, closing the case without a fine. Sanofi must avoid disparaging Fluad in German/French HCP marketing through March 2030 and state on its websites for two years that national bodies treat Efluelda and Fluad as equivalent. A reminder that HD/adjuvanted 65+ share gains now carry competition-law risk alongside clinical differentiation.

Disruptor watch

CD388/MK-1406: Merck says up to $5bn - we model the scenario

Cidara/Merck's drug-Fc conjugate targeting neuraminidase enters Phase 3 (ANCHOR study). With combined efficacy of 60-90%, it could expand the total prevention market. Phase 3 primary data expected H2 2026.

Deals & combination pipeline

Sanofi-Novavax flu/COVID combo hits Phase 3 - $125m milestone triggered

On 29 Oct 2026, Novavax confirmed Sanofi had dosed the fifth participant in a European Phase 3 trial combining Novavax's Nuvaxovid with Sanofi's Efluelda/Fluzone High-Dose in adults 60+, triggering a $125m milestone payment under their licensing agreement. A further $75m is due on manufacturing tech transfer (expected mid-2027) and $225m on a US combination-vaccine launch - the clearest sign yet of a credible flu/COVID combo route to market.

Sample data

A glimpse of the model output

The table below shows a partial view of regional volume and value. Country-level detail, manufacturer splits and scenario outputs are in the licensed Excel model.

Region Doses 2025 (est.) Share of global vol. Market value 2025 2030 forecast
USA~133m21%$2.98bn$5.45bn (base)
West (ex-USA)~119m18%$1.42bn (EU11)Modelled
ROW (37 nations + PAHO)~391m61%ModelledModelled
Brazil breakdown██m██%$██m$██m
China (recalibrated)██m██%+$200m adj.$██m
Japan (recalibrated)██m██%$██m$██m
mRNA penetration - USA--Start yr: 2026~~1.0% penetration
🔒
Full model in the licensed workbook
48 countries · manufacturer splits · mRNA scenarios · 2040 outlook
Request access →
Deliverables

What you receive

The licensed model is a decision-ready intelligence tool - not a static report. All outputs are formula-driven and scenario-ready.

  • MS Excel demand model -48-country volume and value outputs, manufacturer revenue splits, regional breakdowns and scenario toggles
  • mRNA scenario module - base, upside and conservative mRNA penetration assumptions for the USA and ex-US markets through 2030 and 2040
  • Manufacturer intelligence section - Sanofi, CSL Seqirus, GSK and ModernaTX pipeline, pricing and strategy assessed and ranked
  • Disruptor product analysis - CD388/MK-1406 (Merck/Cidara) and OVX836 (Osivax/Meiji) modelled as separate upside scenario
  • New 2031-2040 decade model - first edition to extend the outlook to 2040, with CAGR analysis by region and manufacturer type
  • Executive presentation - PowerPoint deck covering key storylines, charts and strategic commentary; supplied alongside the Excel workbook
  • VacZine Analytics briefing call - available on request to walk through findings and answer client-specific questions
Target audience

Built for organisations making real commercial decisions in influenza

The May 2026 edition is most valuable to teams that need to reconcile the mRNA delay, the disruptor pipeline and the shifting manufacturer landscape into a coherent forecast position.

💊

Vaccine manufacturers

Competitive benchmarking, pricing strategy and country-level opportunity assessment across 48 markets.

📈

Corporate strategy & BD

Validate investment theses around mRNA, combination vaccines and disruptor products against an independent model.

🔬

R&D & pipeline leadership

Understand whether mRNA differentiation - or a cell-based / adjuvanted strategy - is the more defensible near-term commercial position.

🏦

Investors & analysts

Independent validation of manufacturer revenue trajectories and realistic mRNA penetration assumptions for influenza specifically.

🏛️

Procurement & health authorities

Understanding the competitive supply landscape, pricing dynamics and pipeline maturity for national procurement planning.

📋

Market access & HEOR

Competitive context for payer dossiers - particularly for HD, cell-based and mRNA premium positioning arguments.

About this analysis · VAMV036

The VacZine Analytics seasonal influenza model has been maintained continuously since 2007, making it one of the longest-running independent demand models in vaccine market intelligence. The May 2026 edition represents the most substantial revision in the model's history - driven by mRNA delays, manufacturer strategy pivots and the arrival of credible disruptor technologies.

All outputs are validated against manufacturer-reported revenues. The model is built and maintained by VacZine Analytics' own analysts - not aggregated from third-party databases. For enquiries about methodology or a sample, contact us directly.

MarketVIEW · VAMV036 · May 2026

License the May 2026 edition

Contact VacZine Analytics for pricing, sample data and licensing terms. Single-licence and multi-user options available. Briefing calls included.